Last reviewed · How we verify
activated recombinant human factor VII
activated recombinant human factor VII is a Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved. Also known as: NovoSeven®, rFVIIa, F7.
Activated recombinant human factor VII is a protein-based treatment used to manage bleeding disorders, including congenital bleeding disorders, haemophilia A with inhibitors, haemophilia B with inhibitors, acquired bleeding disorder, and bleeding during or following surgery. It works by interacting with coagulation factor IX to facilitate blood clotting.
At a glance
| Generic name | activated recombinant human factor VII |
|---|---|
| Also known as | NovoSeven®, rFVIIa, F7 |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors (PHASE4)
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery (PHASE4)
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor (PHASE3)
- Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors (PHASE2)
- Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation (PHASE2)
- Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
- Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- activated recombinant human factor VII CI brief — competitive landscape report
- activated recombinant human factor VII updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about activated recombinant human factor VII
What is activated recombinant human factor VII?
Who makes activated recombinant human factor VII?
Is activated recombinant human factor VII also known as anything else?
What development phase is activated recombinant human factor VII in?
Related
- Manufacturer: Novo Nordisk A/S — full pipeline
- Also known as: NovoSeven®, rFVIIa, F7
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing